Johnson & Johnson (NYSE: JNJ): Corporate Profile & Financials

Source: Johnson & Johnson Form 10-K 2025

📋 Quick Facts / Company Snapshot

🏢 The Corporate Identity: Who They Are & Where They Came From

The Big Picture

Johnson & Johnson is an international healthcare enterprise structured as a holding company, operating across virtually all countries of the world with an overarching commitment to products related to human health and well-being. The company employs approximately 138,200 full-time equivalent personnel worldwide engaged in the research, development, manufacture, and commercial distribution of therapeutic medicines and medical technologies.

Operating through a decentralized subsidiary structure, senior management teams across domestic and international operating units oversee day-to-day operations and strategic commercial execution within guidelines established by executive leadership. Corporate oversight and strategic priorities emanate from the Executive Committee, while executive leadership rests with the Chief Executive Officer, who serves as the Chief Operating Decision Maker (CODM).

• Total Full-Time Equivalent Employees: Approximately 138,200 worldwide as of December 28, 2025, operating in virtually every global geography.
• Primary Global Operating Structure: Two distinct operational segments consisting of Innovative Medicine and MedTech.
• Foundational Operational Creed: The enterprise operates under Our Credo, detailing institutional responsibilities to patients, consumers, customers, healthcare professionals, employees, communities, and shareholders.

The Journey: History & Evolution

Johnson & Johnson was incorporated in the State of New Jersey in 1887. Over its multi-generational history, the enterprise expanded from its historical roots into a healthcare group spanning prescription pharmaceuticals, medical interventions, and consumer products. The business model has periodically undergone strategic structural reconfigurations to sharpen capital allocation, align with technological evolution, and focus operational attention on high-growth, high-margin healthcare areas.

A transformative historical reorganization reached completion across fiscal 2023 and 2024 through the complete separation of the Consumer Health business. On May 8, 2023, Kenvue Inc. completed an initial public offering (IPO) of 198,734,444 common shares, leaving Johnson & Johnson with an 89.6% ownership stake. On August 23, 2023, the enterprise completed a major exchange offer disposing of an additional 80.1% ownership in exchange for 190,955,436 shares of Johnson & Johnson common stock. The remaining 9.5% stake was fully divested in May 2024 via a debt-for-equity exchange for commercial paper, leaving the company entirely focused on Innovative Medicine and MedTech.

• State and Year of Incorporation: Incorporated in New Jersey in 1887.
• Separation of Consumer Health: Deconsolidation of Kenvue completed via exchange offer on August 23, 2023, resulting in a non-cash gain of $21.0 billion in discontinued operations.
• Full Disentanglement from Kenvue: Completed on May 17, 2024, through a debt-for-equity exchange satisfying $3.6 billion of commercial paper debt.
• Planned Orthopaedics Separation: Announced in October 2025 to separate the Orthopaedics business within 18 to 24 months.

The Corporate Umbrella

Johnson & Johnson functions as the parent holding entity for dozens of domestic and foreign operational operating companies, including Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, Aragon Pharmaceuticals, Inc., Actelion Pharmaceuticals Ltd, Biosense Webster, Inc., Ethicon, Inc., DePuy Orthopaedics, Inc., and Abiomed, Inc. Within the strategic parameters provided by the Executive Committee, operating units manage commercial supply, research trials, regulatory compliance, and regional distribution networks across North America, Europe, the Western Hemisphere, and the Asia-Pacific and Africa regions.

To insulate the operating business and manage catastrophic product claims, Johnson & Johnson maintains a wholly owned captive insurance company. Corporate restructurings within subsidiaries have also been deployed to address mass tort claims, such as the creation of LTL Management LLC (subsequently LLT Management LLC), Red River Talc, LLC, and Pecos River Talc LLC to channel cosmetic talc liabilities.

⚙️ The Business Engine: What They Do & Where They Operate

The Core Divisions

Johnson & Johnson operates across two reportable commercial segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on human therapeutics spanning Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism. Products are distributed directly to retailers, wholesalers, healthcare distributors, hospitals, and medical professionals for prescription use.

The MedTech segment develops, manufactures, and distributes medical technologies used across Cardiovascular, Orthopaedics, Surgery, and Vision fields. These products address disease states where acute and elective procedural intervention plays a central role. MedTech supplies products to healthcare systems, hospital facilities, surgical clinics, and eye care professionals worldwide.

The financial dynamic between the two operating engines illustrates a stark divergence in operational margin profiles. Innovative Medicine delivered an operating margin of 36.9% before corporate allocations, supported by high-volume oncology therapies, whereas MedTech operated at 12.2%, weighed down by legal settlements, restructuring programs, and medical device regulatory costs.

• Innovative Medicine Operational Expansion: Worldwide sales climbed 6.0% (5.3% operational growth and 0.7% positive currency effect), driven by a 22.1% sales expansion in Oncology.
• MedTech Volume Growth: Sales grew 6.1% to $33.8 billion (5.4% operational growth and 0.7% currency benefit), powered by a 15.8% surge in Cardiovascular technologies.
• Corporate Unallocated Net Income: Corporate income before tax included $(6,202) million of net non-allocated income, driven by the reversal of approximately $7.0 billion of previously accrued talc litigation reserves.

The Global Product Catalog

The enterprise develops, manufactures, and delivers human pharmaceuticals and procedural medical devices across several primary franchises. Each product is engineered to address acute clinical pathologies, from hematologic malignancies and chronic autoimmune disorders to interventional cardiology and joint arthroplasty.

The oncology therapeutic area represents the single largest commercial driver within the entire conglomerate, generating more than one-quarter of total worldwide net revenue. Double-digit expansion across DARZALEX, CARVYKTI, and ERLEADA offset sharp revenue erosion in legacy immunology treatments facing biosimilar entry.

The Names You Know

The enterprise owns and licenses an extensive portfolio of brand names and therapeutic proprietary compounds. Patent coverage, exclusivity rights, and brand recognition form the commercial framework supporting market access across international territories.

Revenue composition within the brand catalog indicates that DARZALEX represents the company’s single largest commercial medicine, generating 15.0% of total revenue. Conversely, STELARA—previously the dominant immunology pillar—fell to 6.5% of sales following global biosimilar erosion.

Mapping the Global Reach

Johnson & Johnson operates commercial entities across all major geographic regions. Operations outside the United States accounted for approximately 43% of total enterprise sales in fiscal 2025, distributed across Europe, the Western Hemisphere (excluding the U.S.), and the Asia-Pacific and Africa regions.

The geographic data reveals substantial divergence between operational execution and translational currency impact. In the Western Hemisphere (excluding the U.S.), strong local operational growth of 8.4% was curtailed by a 5.0% currency penalty, whereas European top-line growth of 6.5% was boosted by a 4.1% favorable currency tailwind over a modest 2.4% operational gain.

• Domestic Revenue Dominance: U.S. operations delivered $53.8 billion, representing 57.07% of consolidated global top-line revenue.
• Wholesale Customer Concentration: Three primary wholesale distributors accounted for approximately 21.8%, 15.5%, and 11.1% of total gross consolidated revenues in 2025.
• Long-Lived Asset Location: Of the $121.1 billion in long-lived segment assets, $89.4 billion reside in the United States and $28.0 billion are located in Europe.

The Brick & Mortar Footprint

The corporate manufacturing network encompasses 63 dedicated manufacturing facilities occupying approximately 10.4 million square feet of aggregate floor space. The enterprise primarily owns its production properties to maintain end-to-end quality assurance, though select non-U.S. manufacturing sites and commercial administrative offices are operated under leasehold agreements.

The operational square footage is evenly divided across segments, with Innovative Medicine occupying 5,245 thousand square feet and MedTech utilizing 5,118 thousand square feet. Outside the domestic market, the company maintains 16 production sites for pharmaceuticals and 25 for medical devices, complemented by leased warehouses and regional headquarters.

📊 The Financial Health: The Global Numbers Simplified

Earnings, Expenses, & Take-Home Profits

The consolidated statement of earnings records top-line volume gains, operating cost trends, non-operating litigation movements, and tax provisions for fiscal years 2025, 2024, and 2023.

The doubling of diluted earnings per share from continuing operations in fiscal 2025 ($11.03 versus $5.79 in 2024) stems primarily from a massive swing in Other (income) expense, net. During 2025, Other income included the reversal of approximately $7.0 billion of previously accrued talc reserves following the dismissal of the Red River bankruptcy case, compared to fiscal 2024, which absorbed $5.1 billion of talc charges.

• R&D Spending Contraction: Research and development declined 14.9% to $14.7 billion due to the absence of the 2024 upfront acquired IPR&D charges for Yellow Jersey ($1.25 billion) and V-Wave ($0.5 billion).
• Effective Tax Rate Progression: The worldwide effective income tax rate climbed to 17.7% in 2025 from 15.7% in 2024, driven by a $1.0 billion deferred tax remeasurement under the One Big Beautiful Bill Act (OBBBA).
• Gross Margin Headwinds: Cost of products sold increased to 32.12% of revenue from 30.93% in 2024, impacted by unfavorable product mix from STELARA declines, transactional currency, and MedTech tariffs.

Assets, Debts, & Corporate Wealth

The consolidated balance sheet depicts the capital structure, working capital positions, debt leverage, and shareholders’ equity as of December 28, 2025 and December 29, 2024.

The balance sheet expansion reflects aggressive strategic acquisitions financed by bond issuances. Net intangible assets and goodwill rose by $17.4 billion following the acquisitions of Intra-Cellular Therapies and Halda Therapeutics. Concurrently, long-term debt increased to $39.4 billion following the issuance of $9.2 billion of senior unsecured notes.

• Net Debt Leverage Increase: Net debt expanded from $12.1 billion at year-end 2024 to $27.8 billion at year-end 2025.
• Total Debt to Capital Ratio: Total borrowings reached $47.9 billion, representing 37.0% of total capital, up from 34.0% in 2024.
• Book Value Expansion: Shareholders’ equity per share increased to $33.86 compared to $29.70 at year-end 2024.

Cash Flow: Tracking the Money Movement

The statement of cash flows tracks operating receipts, capital investments, business acquisitions, debt management, and shareholder distributions across fiscal years 2025, 2024, and 2023.

Operating cash flows remained robust at $24.5 billion, providing the internal liquidity necessary to sustain $18.3 billion in shareholder distributions via dividends ($12.4 billion) and share buybacks ($6.0 billion). However, heavy M&A spending of $17.5 billion resulted in an overall cash burn of $4.4 billion for the year.

Funding the Future: R&D and Expansion Spending

The enterprise sustains long-term competitiveness by allocating substantial capital toward in-house clinical pipelines, facility construction, and commercial partnerships. In fiscal 2025, aggregate R&D expenditure reached $14,665 million, representing 15.6% of total revenue. Of this total, $11,827 million was directed to Innovative Medicine (19.6% of segment sales) and $2,838 million was invested in MedTech (8.4% of segment sales).

The enterprise faces material future cash outlays under contractual debt schedules and litigation liabilities. Contractual maturities of long-term debt and interest obligations as of December 28, 2025 are scheduled as follows:

In addition to contractual debt servicing, the company’s near-term operational liquidity must support approximately $3.4 billion in remaining talc litigation reserves, of which one-third is classified as a current liability, alongside approximately $1.1 billion in remaining settlement commitments to resolve nationwide opioid litigation.

🗺️ The Corporate Family Tree: Structure & Investments

Subsidiaries, Associates, & Shared Ventures

The enterprise operates via specialized operating subsidiaries, product licensing agreements, and joint development partnerships across its therapeutic and medtech platforms:

• Intra-Cellular Therapies, Inc.: Wholly acquired on April 2, 2025, for total consideration of $14.5 billion, providing full ownership of CAPLYTA (lumateperone) and clinical neuroscience assets.
• Halda Therapeutics OpCo, Inc.: Wholly acquired on December 26, 2025, for $3.05 billion net of cash acquired, providing proprietary RIPTAC platform assets for prostate and solid tumor oncology.
• Shockwave Medical, Inc.: Wholly acquired on May 31, 2024, for $12.6 billion ($11.5 billion net of cash acquired), establishing the MedTech intravascular lithotripsy franchise.
• Ambrx Biopharma, Inc.: Wholly acquired on March 7, 2024, for $1.8 billion net of cash acquired, integrating synthetic biology antibody-drug conjugate (ADC) technologies.
• Proteologix, Inc.: Wholly acquired on June 20, 2024, for $0.8 billion net of cash acquired, adding bispecific antibody immunology programs.
• Janssen Biotech, Inc. & Genmab A/S: Exclusive global license partner for DARZALEX; royalty payments to Genmab reached $2.4 billion in 2025 and $2.0 billion in 2024.
• Pharmacyclics LLC (an AbbVie company): Co-commercialization and collaboration partner for blood-cancer therapy IMBRUVICA.
• Legend Biotech USA Inc. & Ireland Ltd.: Strategic collaboration partner for the development and worldwide commercialization of CARVYKTI.
• Bayer HealthCare AG: Development collaboration partner for oral anticoagulant XARELTO.
• DePuy Synthes / DePuy Orthopaedics, Inc.: Orthopaedics subsidiary platform subject to the planned corporate separation announced in October 2025.

Strategic Investments & Minority Stakes

Through its corporate venture arm, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), the company invests in early-stage biotechnology and healthcare enterprises. In addition, the company holds debt and equity securities to support liquidity and pension operations.

👥 Power & Control: Who Pulls the Strings?

The Brain Trust: Board of Directors & Executive Leadership

The enterprise is directed by senior executive leaders and corporate governance committees overseeing operational accountability, research prioritization, and compliance:

• Joaquin Duato: Chairman of the Board of Directors and Chief Executive Officer (serving as Principal Executive Officer and Chief Operating Decision Maker).
• Joseph J. Wolk: Executive Vice President, Chief Financial Officer (overseeing corporate finance, accounting, treasury, and capital markets execution).
• Chief Information Officer (CIO): Member of the Executive Committee responsible for IT risk management and enterprise architecture.
• Chief Information Security Officer (CISO): Leads enterprise cybersecurity and incident response; possesses over 25 years of information security experience.
• Regulatory Compliance & Sustainability Committee (RCSC): Committee of the Board of Directors with primary oversight of cybersecurity, data privacy, and healthcare compliance.
• Executive Committee: The senior leadership body responsible for setting enterprise strategy, capital allocations, and organizational priorities.

Who Owns the Stock?

As of February 6, 2026, Johnson & Johnson had 2,409,898,936 shares of common stock outstanding, par value $1.00 per share. As of February 4, 2026, the equity base was held across 108,358 shareholders of record.

The enterprise maintains significant share balances in treasury stock as part of its ongoing capital management and employee compensation settlement strategies. Common shares held in treasury at cost totaled 711,904,000 shares at year-end 2025 ($75,624 million) compared to 712,921,000 shares at year-end 2024 ($75,680 million). During fiscal 2025, the company repurchased 33,903,000 common shares on the open market for an aggregate outlay of $5,953 million.

🎯 The Strategic Outlook: Future Plans & Potential Pitfalls

Competitive Advantages & Economic Moats

The enterprise derives substantial competitive moats from its extensive clinical research infrastructure, global commercial scale, and therapeutic focus in complex medical indications:

• Deep Clinical Innovation Engine: Products introduced within the prior five years accounted for approximately 25% of total fiscal 2025 sales, supported by $14.7 billion in research and development funding.
• Unmatched Oncology Scale: Oncology franchise revenue reached $25.4 billion in 2025, driven by market-leading positions in multiple myeloma therapies (DARZALEX, CARVYKTI, TECVAYLI, TALVEY).
• Interventional Cardiovascular Technology Moat: Targeted M&A has concentrated first-in-class cardiac devices within MedTech, pairing Abiomed’s Impella mechanical circulatory support with Shockwave’s intravascular lithotripsy systems.
• End-to-End Global Manufacturing Scale: A network of 63 proprietary production plants across 10.4 million square feet provides high-yield biomanufacturing and procedural device fabrication.

What Could Go Wrong? Key Challenges & Business Risks

The enterprise faces complex operational, legal, and macroeconomic challenges across its operating units:

• U.S. Pricing Legislation (Inflation Reduction Act): Beginning in 2026, government-mandated price controls take effect for XARELTO, STELARA, and IMBRUVICA under Medicare Part D. In January 2026, CMS selected ERLEADA for 2028 price negotiations. Ongoing constitutional litigation brought by Janssen against HHS and CMS is pending review at the U.S. Supreme Court.
• Biosimilar Patent Cliffs: STELARA net sales declined 41.3% worldwide in 2025 due to global biosimilar market entrants, exerting a 6.2% drag on total enterprise operational sales. Approaching generic exposure for OPSUMIT in 2026 and prospective SIMPONI biosimilars pose additional revenue risks.
• Mass Tort & Product Liability Litigation: The company faces 74,360 direct personal injury lawsuits alleging talc powders caused ovarian cancer and mesothelioma. Following the March 2025 dismissal of the Red River bankruptcy case, the enterprise returned to the tort trial system. Remaining talc reserves stand at $3.4 billion, alongside pelvic mesh, hip implant, and opioid litigation.
• Auris Health Shareholder Judgment: In January 2026, the Delaware Supreme Court affirmed an adverse $0.8 billion breach of contract judgment against Ethicon regarding the 2019 Auris acquisition, which was paid in January 2026.
• International Trade and Geopolitical Headwinds: Operations contend with tariffs, Chinese volume-based procurement (VBP) pricing reductions across surgical and orthopaedic devices, and high-inflation accounting adjustments across Argentina, Turkey, Venezuela, and Egypt.

The Next Chapter: Growth & Expansion Initiatives

Management’s corporate roadmap centers on optimizing capital deployment into high-growth pharmaceutical disease states and separating non-core or procedural assets:

• Execution of Orthopaedics Spin-Off: In October 2025, the company announced its intent to separate the DePuy Synthes Orthopaedics business within 18 to 24 months, allowing MedTech to focus resources on higher-growth cardiovascular and surgical technologies.
• Neuroscience Expansion via CAPLYTA: Following the $14.5 billion acquisition of Intra-Cellular Therapies, management achieved U.S. FDA approval in late 2025 for CAPLYTA as an adjunctive treatment for Major Depressive Disorder, and is pursuing clinical trials in Alzheimer’s-related psychosis and agitation.
• Oncology Line Extensions and Approvals: Fiscal 2025 pipeline advancements included regulatory submissions and approvals for subcutaneous DARZALEX in smoldering multiple myeloma (AQUILA), AKEEGA in metastatic prostate cancer (AMPLITUDE), and subcutaneous RYBREVANT (PALOMA-3).
• Immunology Portfolio Transition: Accelerating regulatory approvals for TREMFYA across Ulcerative Colitis and Crohn’s Disease (GALAXI, GRAVITI, and QUASAR trials) to replace STELARA revenues, alongside submissions for oral peptide ICOTYDE (icotrokinra) in psoriasis.

The Verdict: Strategic Outlook & Conclusion

Johnson & Johnson is undergoing a deliberate structural transformation into a focused biopharmaceutical and interventional medical technology powerhouse. The full divestiture of Kenvue and the planned separation of the Orthopaedics business demonstrate management’s commitment to shedding lower-margin operations and directing capital toward innovative therapeutic assets.

While near-term performance contends with biosimilar erosion in legacy immunology drugs, Medicare Part D pricing mandates, and unpredictable talc trial litigation, the company’s financial foundation remains anchored by $24.5 billion in annual operating cash flow, robust double-digit expansion across Oncology and Cardiovascular platforms, and an active internal R&D pipeline supported by over $14.6 billion in annual investment.

Official Site: https://www.jnj.com